JP2016519063A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519063A5
JP2016519063A5 JP2016502078A JP2016502078A JP2016519063A5 JP 2016519063 A5 JP2016519063 A5 JP 2016519063A5 JP 2016502078 A JP2016502078 A JP 2016502078A JP 2016502078 A JP2016502078 A JP 2016502078A JP 2016519063 A5 JP2016519063 A5 JP 2016519063A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
retinal
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519063A (ja
JP6483083B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026224 external-priority patent/WO2014160281A2/en
Publication of JP2016519063A publication Critical patent/JP2016519063A/ja
Publication of JP2016519063A5 publication Critical patent/JP2016519063A5/ja
Application granted granted Critical
Publication of JP6483083B2 publication Critical patent/JP6483083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502078A 2013-03-14 2014-03-13 治療用化合物の眼への送達を増強する方法 Active JP6483083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785015P 2013-03-14 2013-03-14
US61/785,015 2013-03-14
PCT/US2014/026224 WO2014160281A2 (en) 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018228150A Division JP2019055980A (ja) 2013-03-14 2018-12-05 治療用化合物の眼への送達を増強する方法

Publications (3)

Publication Number Publication Date
JP2016519063A JP2016519063A (ja) 2016-06-30
JP2016519063A5 true JP2016519063A5 (https=) 2017-04-13
JP6483083B2 JP6483083B2 (ja) 2019-03-13

Family

ID=50687629

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502078A Active JP6483083B2 (ja) 2013-03-14 2014-03-13 治療用化合物の眼への送達を増強する方法
JP2018228150A Pending JP2019055980A (ja) 2013-03-14 2018-12-05 治療用化合物の眼への送達を増強する方法
JP2020188684A Pending JP2021038240A (ja) 2013-03-14 2020-11-12 治療用化合物の眼への送達を増強する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018228150A Pending JP2019055980A (ja) 2013-03-14 2018-12-05 治療用化合物の眼への送達を増強する方法
JP2020188684A Pending JP2021038240A (ja) 2013-03-14 2020-11-12 治療用化合物の眼への送達を増強する方法

Country Status (6)

Country Link
US (3) US9730888B2 (https=)
EP (1) EP2968476B1 (https=)
JP (3) JP6483083B2 (https=)
AU (2) AU2014243925B2 (https=)
CA (1) CA2903545C (https=)
WO (1) WO2014160281A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
CA3034887A1 (en) * 2016-08-29 2018-03-08 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
US11932679B2 (en) * 2016-09-02 2024-03-19 Keio University Agent for restoring visual function or agent for preventing deterioration in visual function
US11261236B2 (en) 2017-01-06 2022-03-01 Kyungpook National University Industry-Academic Cooperation Foundation Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
WO2018181071A1 (ja) * 2017-03-28 2018-10-04 森永乳業株式会社 非コラーゲン性糖タンパク質分解用組成物
JP2022533645A (ja) * 2019-05-17 2022-07-25 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
JPWO2021049634A1 (https=) 2019-09-13 2021-03-18
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
US20250186617A1 (en) * 2020-09-17 2025-06-12 Restore Vision Inc. Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness
JP2022184212A (ja) * 2021-05-31 2022-12-13 ユニ・チャーム株式会社 月経血を吸収するための吸収性物品
CN113355309B (zh) * 2021-08-10 2021-11-05 迈威(上海)生物科技股份有限公司 重组截短型人纤维蛋白溶酶制备工艺
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20080248021A1 (en) 2005-06-30 2008-10-09 Ista Pharmaceuticals, Inc. Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2009067407A2 (en) 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
AU2013230112A1 (en) 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use

Similar Documents

Publication Publication Date Title
JP2016519063A5 (https=)
HRP20211453T1 (hr) Liječenje amd uporabom aav sflt-1
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2016534751A5 (https=)
CN115246874B (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
JP2016513669A5 (https=)
JP2013506411A5 (https=)
JP2016505635A5 (https=)
FI4206216T3 (fi) Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi
JP2015500811A5 (https=)
JP2019530440A5 (https=)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2011514314A5 (https=)
JP2011500035A5 (https=)
JP2012525128A5 (https=)
FI4005603T3 (fi) Adeno-assosioituneen viruksen virioneita varianttikapsidin kera ja menetelmiä niiden käyttämiseksi
JP2015509707A5 (https=)
JP2014510519A5 (https=)
US20160031991A1 (en) Targeting vaccines for veterinary use
JP2014510730A5 (https=)
RU2018119014A (ru) АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Bennett et al. Hybrid flagellin as a T cell independent vaccine scaffold
JP2015524413A5 (https=)
JP2014534807A (ja) クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ